p73 and p63 are homotetramers capable of weak heterotypic interactions with each other but not with p53

被引:141
作者
Davison, TS
Vagner, C
Kaghad, M
Ayed, A
Caput, D
Arrowsmith, CH
机构
[1] Ontario Canc Inst, Toronto, ON M5G 2M9, Canada
[2] Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2M9, Canada
[3] Sanofi Rech, F-31280 Labege, France
关键词
D O I
10.1074/jbc.274.26.18709
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Mutations in the p53 tumor suppressor gene are the most frequent genetic alterations found in human cancers, Recent identification of two human homologues of p53 has raised the prospect of functional interactions between family members via a conserved oligomerization domain. Here we report in vitro and in vivo analysis of homo- and hetero-oligomerization of p53 and its homologues, p63 and p73, The oligomerization domains of p63 and p73 can independently fold into stable homotetramers, as previously observed for p53, However, the oligomerization domain of p53 does not associate with that of either p73 or p63, even when p53 is in 15-fold excess. On the other hand, the oligomerization domains of p63 and p73 are able to weakly associate with one another in vitro, In vivo co-transfection assays of the ability of p53 and its homologues to activate reporter genes showed that a DNA-binding mutant of p53 was not able to act in a dominant negative manner over wild-type p73 or p63 but that a p73 mutant could inhibit the activity of wild-type p63, These data suggest that mutant p53 in cancer cells will not interact with endogenous or exogenous p63 or p73 via their respective oligomerization domains. It also establishes that the multiple isoforms of p63 as well as those of p73 are capable of interacting via their common oligomerization domain.
引用
收藏
页码:18709 / 18714
页数:6
相关论文
共 28 条
  • [1] An adenovirus mutant that replicates selectively in p53-deficient human tumor cells
    Bischoff, JR
    Kim, DH
    Williams, A
    Heise, C
    Horn, S
    Muna, M
    Ng, L
    Nye, JA
    SampsonJohannes, A
    Fattaey, A
    McCormick, F
    [J]. SCIENCE, 1996, 274 (5286) : 373 - 376
  • [2] CHEN JY, 1993, ONCOGENE, V8, P2159
  • [3] Di Como CJ, 1999, MOL CELL BIOL, V19, P1438
  • [4] THE TUMOR-SUPPRESSOR P53
    DONEHOWER, LA
    BRADLEY, A
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA, 1993, 1155 (02) : 181 - 205
  • [5] CONFORMATIONAL SHIFTS PROPAGATE FROM THE OLIGOMERIZATION DOMAIN OF P53 TO ITS TETRAMERIC DNA-BINDING DOMAIN AND RESTORE DNA-BINDING TO SELECT P53 MUTANTS
    HALAZONETIS, TD
    KANDIL, AN
    [J]. EMBO JOURNAL, 1993, 12 (13) : 5057 - 5064
  • [6] P53 MUTATIONS IN HUMAN CANCERS
    HOLLSTEIN, M
    SIDRANSKY, D
    VOGELSTEIN, B
    HARRIS, CC
    [J]. SCIENCE, 1991, 253 (5015) : 49 - 53
  • [7] CRYSTAL-STRUCTURE OF THE TETRAMERIZATION DOMAIN OF THE P53 TUMOR-SUPPRESSOR AT 1.7 ANGSTROMS
    JEFFREY, PD
    GORINA, S
    PAVLETICH, NP
    [J]. SCIENCE, 1995, 267 (5203) : 1498 - 1502
  • [8] THERMODYNAMIC ANALYSIS OF THE STRUCTURAL STABILITY OF THE TETRAMERIC OLIGOMERIZATION DOMAIN OF P53 TUMOR-SUPPRESSOR
    JOHNSON, CR
    MORIN, PE
    ARROWSMITH, CH
    FREIRE, E
    [J]. BIOCHEMISTRY, 1995, 34 (16) : 5309 - 5316
  • [9] p73 is a human p53-related protein that can induce apoptosis
    Jost, CA
    Marin, MC
    Kaelin, WG
    [J]. NATURE, 1997, 389 (6647) : 191 - 194
  • [10] Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers
    Kaghad, M
    Bonnet, H
    Yang, A
    Creancier, L
    Biscan, JC
    Valent, A
    Minty, A
    Chalon, P
    Lelias, JM
    Dumont, X
    Ferrara, P
    McKeon, F
    Caput, D
    [J]. CELL, 1997, 90 (04) : 809 - 819